“…FDA approval of DLX for the treatment of MDD was supported by at least 17 controlled trials, including two proof-of-concept studies, two short-term dose-finding trials, four phase-III short-and long-term trials, and one relapse-prevention trial (Goldstein et al, , 2004Detke et al, 2002aDetke et al, ,b, 2004Company, 2004c,f, 2006e;Brannan et al, 2005;Burt et al, 2005;Perahia et al, 2006aPerahia et al, ,b, 2008Brecht et al, 2007;Khan et al, 2007;Lee et al, 2007;Nierenberg et al, 2007;Raskin et al, 2007Raskin et al, , 2008aWade et al, 2007). At least three of these trials remain unpublished in peer-reviewed journals; two did not find statistical superiority of relatively low doses of DLX over PBO (Eli Lilly and Company, 2004c,f).…”